Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Plan B lifts women's health for Teva: Second-quarter sales of the emergency contraceptive help drive a 3.9 percent increase in Teva Pharmaceuticals' women's health business to $80 million. Teva is in the midst of de-stocking Plan B inventory as Plan B One-Step -- a single-pill version of the two-pill original product -- becomes available in August, the Jerusalem-based firm said July 28 (1"The Tan Sheet" July 20, 2009). During a same-day earnings call, President and CEO Shlomo Yanai said the women's health business "has outstanding prospects for growth" and Teva intends to expand its oral contraceptive offerings


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts